Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Lumretuzumab |
Synonyms | |
Therapy Description |
Lumretuzumab (RO5479599) is a humanized anti-Her3 (ERBB3) antibody that binds to and inhibits human epidermal growth factor receptor signaling, leading to growth inhibition in tumors (PMID: 26463709, PMID: 31423336). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Lumretuzumab | RG7116|RO5479599 | HER3 (ERBB3) Antibody 23 | Lumretuzumab (RO5479599) is a humanized anti-Her3 (ERBB3) antibody that binds to and inhibits human epidermal growth factor receptor signaling, leading to growth inhibition in tumors (PMID: 26463709, PMID: 31423336). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ERBB3 positive | Advanced Solid Tumor | sensitive | Lumretuzumab | Phase I | Actionable | In a Phase I trial, Lumretuzumab treatment resulted in stable disease in 21.3% (10/47) of patients with Erbb3 (Her3)-expressing advanced solid tumors (PMID: 26463709). | 26463709 |
ERBB3 positive | triple-receptor negative breast cancer | sensitive | Lumretuzumab | Phase I | Actionable | In a Phase I trial, Lumretuzumab treatment resulted in tumor shrinkage in a patient with Erbb3 (Her3)-expressing triple-receptor negative breast cancer (PMID: 26463709). | 26463709 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|